CBAY

Cymabay Therapeutics
CBAY

Overview Fund Activity
Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

30 hedge funds and large institutions have $12.1M invested in Cymabay Therapeutics in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
30
Holders Change
+1
Holders Change %
+3.45%
% of All Funds
0.8%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
4
Increased
3
Reduced
10
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$68.4K
2
Renaissance Technologies
Renaissance Technologies
New York
+$67.7K
3
Citadel Advisors
Citadel Advisors
Florida
+$15K
4
TRCT
Tower Research Capital (TRC)
New York
+$4.58K
5
Barclays
Barclays
United Kingdom
+$1K

Top Sellers

1
SM
Sabby Management
Florida
-$709K
2
VAM
Visium Asset Management
New York
-$543K
3
LOAMU
Lombard Odier Asset Management (USA)
New York
-$508K
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$258K
5
PVI
Pura Vida Investments
New York
-$195K
Name Holding Trade Value Shares
Change 		Shares
Change %
Geode Capital Management
26
Geode Capital Management
Massachusetts
$132 – – –
VAM
27
Visium Asset Management
New York
– -$543K -321,158 Closed
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
– -$43K -25,405 Closed
VKH
29
Virtu KCG Holdings
New York
– -$32K -18,946 Closed
1
2